Clinical-stage biotechnology company ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS on Wednesday announced the execution of a definitive licensing agreement with Serum Institute of India Pvt. Ltd. for two novel blood-stage malaria vaccines, RH5.1 and R78C.
The agreement builds upon the previously announced term sheet and secures SII's rights to use ExpreS2ion's proprietary production platform, ExpreS2, to further develop, manufacture, and commercialise RH5.1 and R78C.
Under the terms, ExpreS2ion is entitled to upfront and milestone payments, aggregated amounting to low single-digit EUR millions, as well as royalties ranging from below 1% to mid-single digit percentages on future net sales. The collaboration strengthens the commitment of both parties to accelerate access to an innovative malaria vaccine with potential to significantly reduce disease burden worldwide.
Malaria remains a deadly parasitic disease with devastating impacts, particularly on vulnerable populations in low- and middle-income countries. In 2023, there were an estimated 263 million cases of malaria worldwide and approximately 597,000 deaths, with 76% of fatalities occurring in children under five in the African Region.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.